Level C· Early human research exploring benefitsProspective StudyPubMed

Autotransplantation of the Adipose Tissue-Derived Mesenchymal Stromal Cells in Therapy of Venous Stasis Ulcers.

Masłowski L., Paprocka M., Czyżewska-Buczyńska A., Bielawska-Pohl A., Duś D., Grendziak R.

Prospective Study with a reported sample of 11 on Chronic Wound, published in Arch Immunol Ther Exp (Warsz) (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Arch Immunol Ther Exp (Warsz) (2020)
Country
Poland
Reported sample size
11
Source database
PubMed
PMID
32060631
DOI
10.1007/s00005-020-00571-9

Abstract (original English)

Adipose tissue is a reliable source of mesenchymal stromal cells (MSC) for use in regenerative medicine. The aim of this pilot study was to describe the method, and assess the safety and the potential efficacy of transplantation of autologous adipose tissue-derived MSC for the treatment of chronic venous stasis ulcers. Study group consisted of 11 patients (mean age: 66.6 ± 9.5 years) with chronic venous stasis ulcers. Adipose tissue was harvested by tumescent-aspiration method. Stromal cells were separated using a dedicated closed system in a real-time bedside manner. The phenotype of cells was determined immediately after separation. Cell concentrate was implanted subcutaneously around the wound and the wound bed. All ulcers were assessed planimetrically before autotransplantation and every two weeks during the six-month follow-up. During the study all patients received standard local and general treatment. The preparation contained an average of 5.6 × 10 6 ± 4 × 10 6 cells per milliliter. The phenotype of 65-82% of transplanted cells expressed MSC markers: CD73 + CD90 + and CD34 + . An improvement was observed in 75% of ulcers. The data showed highly significant negative correlation (p < 0.0001) between wound size and wound closure degree. There was no correlation of ulcer healing with other parameters evaluated, including age of the patients. No serious side effects were obs

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAgedBiomarkersChronic DiseaseFemaleHumansMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research